866-997-4948(US-Canada Toll Free)

Cancer Cachexia - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Cancer

No. of Pages : 82 Pages


Global Markets Directs, \'Cancer Cachexia Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. 

Cancer Cachexia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cancer Cachexia.
  • A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Cancer Cachexia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Cancer Cachexia 9
Cancer Cachexia Therapeutics under Development by Companies 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Cancer Cachexia Therapeutics - Products under Development by Companies 17
Companies Involved in Cancer Cachexia Therapeutics Development 19
Eli Lilly and Company 19
Aphios Corporation 20
AEterna Zentaris Inc. 21
Santhera Pharmaceuticals Holding AG 22
Helsinn Healthcare S.A. 23
Alder Biopharmaceuticals Inc. 24
Vicus Therapeutics, LLC 25
OHR Pharmaceutical Inc. 26
XBiotech USA, Inc. 27
Acacia Pharma Ltd. 28
Cancer Cachexia - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
macimorelin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
dronabinol - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
clazakizumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
anamorelin hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
anamorelin hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(megestrol + formoterol) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(etodolac + propranolol hydrochloride) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
OHR/AVR-118 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
MT-102 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LY-2495655 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drug For Cancer Cachexia - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Ghrelin Receptor Agonists - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Xilonix - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SNT-207707 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SNT-209858 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug Targeting Vps34 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug Targeting Glutaminase - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drugs For Cancer Cachexia - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
DLN-101 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IP-1510 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cancer Cachexia Therapeutics - Drug Profile Updates 62
Cancer Cachexia Therapeutics - Discontinued Products 71
Cancer Cachexia Therapeutics - Dormant Products 72
Cancer Cachexia - Product Development Milestones 73
Featured News & Press Releases 73
Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology 73
Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix 74
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 74
Jun 25, 2012: GTx Announces Presentation On Enobosarms Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels 75
Mar 30, 2012: XBiotech Announces FDA Approval To Launch Phase II Study Of Xilonix As Treatment For Cachexia In Subjects With Metastatic Cancers 76
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris\'s Ghrelin Agonist, AEZS-130 77
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 77
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 78
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 79
May 17, 2011: Ohr Pharmaceutical Receives Canadian Composition-of-Matter Patent For OHR/AVR118 80

Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Table


Number of Products Under Development for Cancer Cachexia, H1 2013 9
Products under Development for Cancer Cachexia - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Comparative Analysis by Late Stage Development, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Early Clinical Stage Development, H1 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 16
Products under Development by Companies, H1 2013 17
Products under Development by Companies, H1 2013 (Contd..1) 18
Eli Lilly and Company, H1 2013 19
Aphios Corporation, H1 2013 20
AEterna Zentaris Inc., H1 2013 21
Santhera Pharmaceuticals Holding AG, H1 2013 22
Helsinn Healthcare S.A., H1 2013 23
Alder Biopharmaceuticals Inc., H1 2013 24
Vicus Therapeutics, LLC, H1 2013 25
OHR Pharmaceutical Inc., H1 2013 26
XBiotech USA, Inc., H1 2013 27
Acacia Pharma Ltd., H1 2013 28
Assessment by Monotherapy Products, H1 2013 29
Assessment by Combination Products, H1 2013 30
Assessment by Stage and Route of Administration, H1 2013 32
Assessment by Stage and Molecule Type, H1 2013 34
Cancer Cachexia Therapeutics - Drug Profile Updates 62
Cancer Cachexia Therapeutics - Discontinued Products 71
Cancer Cachexia Therapeutics - Dormant Products 72

List of Chart


Number of Products under Development for Cancer Cachexia, H1 2013 9
Products under Development for Cancer Cachexia - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Late Stage Products, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Early Clinical Stage Products, H1 2013 15
Discovery and Pre-Clinical Stage Products, H1 2013 16
Assessment by Monotherapy Products, H1 2013 29
Assessment by Combination Products, H1 2013 30
Assessment by Route of Administration, H1 2013 31
Assessment by Stage and Route of Administration, H1 2013 32
Assessment by Molecule Type, H1 2013 33
Assessment by Stage and Molecule Type, H1 2013 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *